A pericentric inv(9)(p22q34) of the der(9)t(9;22)(q34;q11.2) is a recurrent secondary anomaly in Ph-positive leukemia

Jinlan Pan, Yongquan Xue, Huiying Qiu, Suning Chen, Jun Zhang, Yafang Wu, Juan Shen, Yong Wang
{"title":"A pericentric inv(9)(p22q34) of the der(9)t(9;22)(q34;q11.2) is a recurrent secondary anomaly in Ph-positive leukemia","authors":"Jinlan Pan,&nbsp;Yongquan Xue,&nbsp;Huiying Qiu,&nbsp;Suning Chen,&nbsp;Jun Zhang,&nbsp;Yafang Wu,&nbsp;Juan Shen,&nbsp;Yong Wang","doi":"10.1016/j.cancergencyto.2010.05.009","DOIUrl":null,"url":null,"abstract":"<div><p>A pericentric inv(9)(p22q34) of the derivative chromosome 9 that resulted from a standard t(9;22)(q34;q11.2) was identified by R-banding karyotypic analysis and fluorescence in situ hybridization (FISH) assays in 4 (0.18%) of 2,200 Philadelphia chromosome (Ph)-positive leukemia patients, including 3 with chronic myeloid leukemia (CML) in chronic phase and 1 with acute myeloid leukemia (AML) in our hospital since 2004. All four patients had two malignant clones: one with only t(9;22)(q34;q11.2) and another with der(9)t(9;22)(q34;q11.2)inv(9)(p22q34) that resulted in the separation of the <em>ABL1/BCR</em> fusion gene. No metaphases with only inv(9)(p22q34) were seen in any of them. FISH also found a deletion of partial sequence of BCR on der(9)t(9;22)(q34;q11.2)inv(9)(p22q34) in 67.5% of bone marrow cells in the AML patient, but did not detect the deletion of the sequence of ASS/9q34 in these four patients. Reverse transcriptase–polymerase chain reaction revealed a b3a2 type of <em>BCR/ABL1</em> fusion transcript in all of them, proving their disease to be Ph-positive leukemia. On reviewing the literature, only two solitary Ph-positive leukemia patients have been noticed to have the inv(9)(p22q34) anomaly. These two patients, together with our four documented patients, indicate that inv(9)(p22q34) is a novel, rare, but recurrent secondary chromosomal abnormality for Ph-positive leukemia. Despite receiving hydroxyurea therapy (<em>n</em> = 3 patients), combined chemotherapy (<em>n</em> = 2), even imatinib treatment (<em>n</em> = 1), three patients, including one with AML and two with CML (one of whom progressed into the lymphoblastic blast phase), died with survival times of 28 days, 13 months, and 34 months, respectively. Only one patient with CML remained alive for 5.5 months. Their negative outcome implies that inv(9)(p22q34) has an unfavorable impact on prognosis. Presently, no firm conclusions can be drawn from this study. Because the case number reported here is very small, more patients with this anomaly need to be investigated to elucidate its true prognostic significance.</p></div>","PeriodicalId":55596,"journal":{"name":"Cancer Genetics and Cytogenetics","volume":"203 2","pages":"Pages 333-340"},"PeriodicalIF":0.0000,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cancergencyto.2010.05.009","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Genetics and Cytogenetics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165460810002244","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

A pericentric inv(9)(p22q34) of the derivative chromosome 9 that resulted from a standard t(9;22)(q34;q11.2) was identified by R-banding karyotypic analysis and fluorescence in situ hybridization (FISH) assays in 4 (0.18%) of 2,200 Philadelphia chromosome (Ph)-positive leukemia patients, including 3 with chronic myeloid leukemia (CML) in chronic phase and 1 with acute myeloid leukemia (AML) in our hospital since 2004. All four patients had two malignant clones: one with only t(9;22)(q34;q11.2) and another with der(9)t(9;22)(q34;q11.2)inv(9)(p22q34) that resulted in the separation of the ABL1/BCR fusion gene. No metaphases with only inv(9)(p22q34) were seen in any of them. FISH also found a deletion of partial sequence of BCR on der(9)t(9;22)(q34;q11.2)inv(9)(p22q34) in 67.5% of bone marrow cells in the AML patient, but did not detect the deletion of the sequence of ASS/9q34 in these four patients. Reverse transcriptase–polymerase chain reaction revealed a b3a2 type of BCR/ABL1 fusion transcript in all of them, proving their disease to be Ph-positive leukemia. On reviewing the literature, only two solitary Ph-positive leukemia patients have been noticed to have the inv(9)(p22q34) anomaly. These two patients, together with our four documented patients, indicate that inv(9)(p22q34) is a novel, rare, but recurrent secondary chromosomal abnormality for Ph-positive leukemia. Despite receiving hydroxyurea therapy (n = 3 patients), combined chemotherapy (n = 2), even imatinib treatment (n = 1), three patients, including one with AML and two with CML (one of whom progressed into the lymphoblastic blast phase), died with survival times of 28 days, 13 months, and 34 months, respectively. Only one patient with CML remained alive for 5.5 months. Their negative outcome implies that inv(9)(p22q34) has an unfavorable impact on prognosis. Presently, no firm conclusions can be drawn from this study. Because the case number reported here is very small, more patients with this anomaly need to be investigated to elucidate its true prognostic significance.

der(9)t(9;22)(q34;q11.2)的中心周围异常(9)(p22q34)是ph阳性白血病的复发性继发性异常
通过r -带核型分析和荧光原位杂交(FISH)检测,在我院2004年以来的2200例费城染色体(Ph)阳性白血病患者(3例慢性髓性白血病(CML)慢性期和1例急性髓性白血病(AML))中,鉴定出标准t(9;22)(q34;q11.2)衍生的9号染色体的4例(0.18%)(p22q34)。所有4例患者都有两个恶性克隆:一个只携带t(9;22)(q34;q11.2),另一个携带der(9)t(9;22)(q34;q11.2)inv(9)(p22q34),导致ABL1/BCR融合基因分离。所有病例均未见仅有inv(9)(p22q34)的中期。FISH在67.5%的AML患者骨髓细胞中也发现了der(9)t(9;22)(q34;q11.2)inv(9)(p22q34)上BCR部分序列的缺失,但在这4例患者中未发现ASS/9q34序列的缺失。逆转录聚合酶链反应均显示b3a2型BCR/ABL1融合转录物,证实其为ph阳性白血病。回顾文献,只有两例单独的ph阳性白血病患者被发现有inv(9)(p22q34)异常。这两个病人,连同我们的四个记录的病人,表明inv(9)(p22q34)是一个新的,罕见的,但复发的继发性染色体异常ph阳性白血病。尽管接受了羟基脲治疗(n = 3例),联合化疗(n = 2),甚至伊马替尼治疗(n = 1),但3例患者死亡,其中1例为AML, 2例为CML(其中1例进展到淋巴母细胞期),生存时间分别为28天,13个月和34个月。只有一名CML患者存活了5.5个月。他们的阴性结果提示inv(9)(p22q34)对预后有不利影响。目前,这项研究还不能得出确切的结论。由于这里报告的病例数量非常少,需要对更多的患者进行调查,以阐明其真正的预后意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
>12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信